CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 23 enrolled
Drug / intervention
N-Acetylcysteine (NAC) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01993849
NCT01993849Phase 3Completed

A Randomized Placebo-controlled Trial of N-Acetylcysteine in Onychophagia

Kevin Gray, MD·interventional·Posted Nov 25, 2013·Updated Oct 3, 2018

In Brief

A Phase 3 clinical trial evaluating N-Acetylcysteine (NAC) and Placebo for Onychophagia. Completed, enrolled 23 participants across 1 site.

Detailed Summary

To conduct a pilot randomized placebo-controlled feasibility trial of N-acetylcysteine (NAC) in onychophagia, preliminarily assessing the tolerability and effects of this pharmacotherapy on young adults who bite their fingernails. It is proposed that NAC will help decrease fingernail biting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnychophagia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 25, 2013
Enrollment StartOct 1, 2013
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.6 years ago

Interventions

N-Acetylcysteine (NAC)drug

This is the medication N-acetylcysteine (NAC)

Placeboother

Placebo, designed to match in appearance to NAC